Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

NCT05675033 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

50

Enrollment

OTHER_GOV

Sponsor class

Conditions

Lung Adenocarcinoma
Stage IV Non-small Cell Lung Cancer
PD-1 Inhibitor
VEGF

Interventions

DRUG: Serplulimab and Bevacizumab injection

Sponsor

Fujian Cancer Hospital